Novavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020
November 03 2020 - 8:00AM
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, today announced it will report its third quarter 2020
financial and operating results following the close of U.S.
financial markets on Monday, November 9, 2020.
Conference call details are as follows:
Date: |
November 9,
2020 |
Time: |
4:30 p.m. U.S. Eastern Time (ET) |
Dial-in number: |
(877) 212-6076 (Domestic) or (707) 287-9331
(International) |
Passcode: |
8059421 |
Webcast: |
www.novavax.com, “For Investors”/ “Events” |
Conference call and webcast replay:
Dates: |
Starting at
7:30 p.m. ET, November 9, 2020 until |
|
7:30 p.m. ET November 16, 2020 |
Dial-in number: |
(855) 859-2056 (Domestic) or (404) 537-3406
(International) |
Passcode: |
8059421 |
Webcast: |
www.novavax.com, “For Investors”/ “Events”, until February 9,
2021 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage
biotechnology company that promotes improved health globally
through the discovery, development, and commercialization of
innovative vaccines to prevent serious infectious
diseases. Novavax is currently conducting multiple clinical trials
for NVX-CoV2373, its vaccine candidate against the virus that
causes COVID-19, including a pivotal Phase 3 clinical trial in the
United Kingdom to evaluate the efficacy, safety and immunogenicity
in individuals aged 18-84 years of age. NanoFlu™, its quadrivalent
influenza nanoparticle vaccine, met all primary objectives in its
pivotal Phase 3 clinical trial in older adults. Both candidate
vaccines incorporate Novavax’ proprietary saponin-based Matrix-M™
adjuvant to enhance the immune response and stimulate high levels
of neutralizing antibodies. Novavax is a leading innovator of
recombinant vaccines; its proprietary recombinant technology
platform combines the power and speed of genetic engineering to
efficiently produce highly immunogenic nanoparticles in order to
address urgent global health needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Contacts:InvestorsErika Trahanir@novavax.com240-268-2022
MediaBrandzone/KOGS CommunicationEdna
Kaplankaplan@kogspr.com617-974-8659
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From May 2023 to May 2024